Sarilumab monotherapy compared with adalimumab monotherapy for the treatment of moderately to severely active rheumatoid arthritis: an analysis of incremental cost per effectively treated patient

Overview of attention for article published in ClinicoEconomics and Outcomes Research: CEOR, February 2019

Altmetric Badge

Mentioned by

twitter: 1 X user

Citations

dimensions_citation: 7 Dimensions

Readers on

mendeley: 27 Mendeley

Summary X Dimensions citations

So far, Dimensions has found 7 publications that cite this research output.

7

The most recent citing publications are shown below. View all 7 publications that cite this research output on Dimensions.

Cost-effectiveness of tumor necrosis factor-alpha inhibitors: a systematic review and meta-analysis of cost-utility studies

Article in Expert Review of Pharmacoeconomics & Outcomes Research (August 2023)

Cost-effectiveness of janus kinase inhibitors for rheumatoid arthritis: A systematic review and meta-analysis of cost-utility studies

Article in Frontiers in Pharmacology (December 2022)

Cost-utility analyses of targeted immunomodulators in rheumatoid arthritis: systematic review

Article in Journal of Medical Economics (February 2020)